BIOCRYST PHARMACEUTICALS, INC. Accrued Liabilities, Current
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Accrued Liabilities, Current of $121.89 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Accrued Liabilities, Current $121.89M.
- 2026-03-31: Accrued Liabilities, Current $119.40M.
- 2025-12-31: Accrued Liabilities, Current $126.41M.
- 2025-09-30: Accrued Liabilities, Current $118.78M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $121.89M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $119.40M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $126.41M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $118.78M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $107.11M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $92.64M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $113.29M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $104.20M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $89.60M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $79.25M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $102.88M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $77.39M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $75.30M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $75.21M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $87.56M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $69.27M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $79.71M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $63.58M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $72.67M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $56.31M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $48.77M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $32.72M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $33.94M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $30.46M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $24.84M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $20.19M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $21.36M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $24.95M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $19.34M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $16.55M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $15.89M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $15.12M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $19.41M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $15.62M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $12.70M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $11.87M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $12.33M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $11.34M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $10.84M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $10.78M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $11.78M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $17.33M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $16.24M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $23.03M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $19.00M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $12.29M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $11.33M 10-K · filed 2016-02-26 | $11.72M 10-K · filed 2015-03-02 |
| 2014-09-30 | $11.25M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $7.31M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $6.31M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $5.74M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $7.67M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $5.77M 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $5.65M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $9.86M 10-K · filed 2014-03-10 | |
| 2012-09-30 | $8.04M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $8.21M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $9.25M 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $12.62M 10-K · filed 2013-03-11 | |
| 2011-09-30 | $12.03M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $12.31M 10-Q · filed 2011-08-04 | |
| 2010-12-31 | $17.30M 10-K · filed 2012-03-06 | $17.12M 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |